Top Ten Equity Holdings and Exposures

Summary by AI BETAClose X

Polar Capital Global Healthcare Trust plc has disclosed its top ten equity holdings and sector and geographic exposure as of August 28, 2026. The top ten holdings, representing 55.5% of the portfolio, are led by Johnson & Johnson at 9.8% and Eli Lilly & Co at 9.5%. Sector exposure is dominated by Pharmaceuticals (40.6%) and Biotechnology (22.3%), with a significant geographic concentration in the United States (68.4%).

Disclaimer*

Polar Capital Global Health Tst PLC
04 September 2026
 

4th September 2026

 

Polar Capital Global Healthcare Trust plc (the "Company")

 

Top Ten Equity Holdings and Sector and Geographic Exposure as at 28th August 2026.

 

Polar Capital Global Healthcare Trust plc is pleased to announce that as at 28th August 2026 the top ten equity holdings and the sector and geographic breakdown were as follows:

 

Top 10 Holdings         

%

Johnson & Johnson

9.8%

Eli Lilly & Co

9.5%

UnitedHealth Group

6.2%

Roche Holding AG

5.6%

Abbott Laboratories

5.6%

Teva Pharmaceutical Industries

4.3%

Danaher

4.0%

IQVIA Holdings

3.8%

AstraZeneca

3.6%

Agilent Technologies

3.0%

Total

55.5%

 

Sector Exposure

%

Pharmaceuticals

40.6%

Biotechnology

22.3%

Healthcare Equipment

13.5%

Life Sciences Tools & Services

13.0%

Managed Healthcare

6.2%

Healthcare Supplies

5.2%

Healthcare Services

4.8%

Healthcare Distributors

1.9%

Healthcare Technology

0.9%

Healthcare Facilities

0.0%

Cash

-8.5%

Total

100.0%

 

Geographic Exposure

%

United States

68.4%

United Kingdom

6.0%

Switzerland

5.6%

Israel

4.3%

Canada

3.7%

Japan

3.0%

Denmark

2.5%

China

2.4%

Italy

2.2%

Germany

2.1%

India

2.0%

Ireland

1.9%

Netherlands

1.7%

Sweden

1.6%

Cash

-8.5%

Total

100.0%

 

The monthly factsheet will usually be available on the Company's website on the 10th working day after the month end and includes a commentary by the investment manager.  www.Polarcapitalhealthcaretrust.com

Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings